Cargando…
P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430995/ http://dx.doi.org/10.1097/01.HS9.0000971240.72498.b6 |
| _version_ | 1785091093341143040 |
|---|---|
| author | Kumode, Takahiro Munakata, Wataru Goto, Hideki Fukuhara, Noriko Shimoyama, Tatsu Takeuchi, Masahiro Kawakita, Toshiro Kubo, Kohmei Sawa, Masashi Uchida, Toshiki Mishima, Yuko Ichii, Michiko Hanaya, Miyoko Matsumoto, Asuka Kuriki, Masaaki Izutsu, Koji Ishizawa, Kenichi |
| author_facet | Kumode, Takahiro Munakata, Wataru Goto, Hideki Fukuhara, Noriko Shimoyama, Tatsu Takeuchi, Masahiro Kawakita, Toshiro Kubo, Kohmei Sawa, Masashi Uchida, Toshiki Mishima, Yuko Ichii, Michiko Hanaya, Miyoko Matsumoto, Asuka Kuriki, Masaaki Izutsu, Koji Ishizawa, Kenichi |
| author_sort | Kumode, Takahiro |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430995 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104309952023-08-17 P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE Kumode, Takahiro Munakata, Wataru Goto, Hideki Fukuhara, Noriko Shimoyama, Tatsu Takeuchi, Masahiro Kawakita, Toshiro Kubo, Kohmei Sawa, Masashi Uchida, Toshiki Mishima, Yuko Ichii, Michiko Hanaya, Miyoko Matsumoto, Asuka Kuriki, Masaaki Izutsu, Koji Ishizawa, Kenichi Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430995/ http://dx.doi.org/10.1097/01.HS9.0000971240.72498.b6 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Kumode, Takahiro Munakata, Wataru Goto, Hideki Fukuhara, Noriko Shimoyama, Tatsu Takeuchi, Masahiro Kawakita, Toshiro Kubo, Kohmei Sawa, Masashi Uchida, Toshiki Mishima, Yuko Ichii, Michiko Hanaya, Miyoko Matsumoto, Asuka Kuriki, Masaaki Izutsu, Koji Ishizawa, Kenichi P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE |
| title | P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE |
| title_full | P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE |
| title_fullStr | P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE |
| title_full_unstemmed | P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE |
| title_short | P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE |
| title_sort | p1086: efficacy and safety of zandelisib administered by intermittent dosing in japanese patients with relapsed/refractory indolent b-cell non-hodgkin’s lymphoma: primary analysis of the phase 2 study mirage |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430995/ http://dx.doi.org/10.1097/01.HS9.0000971240.72498.b6 |
| work_keys_str_mv | AT kumodetakahiro p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT munakatawataru p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT gotohideki p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT fukuharanoriko p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT shimoyamatatsu p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT takeuchimasahiro p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT kawakitatoshiro p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT kubokohmei p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT sawamasashi p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT uchidatoshiki p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT mishimayuko p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT ichiimichiko p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT hanayamiyoko p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT matsumotoasuka p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT kurikimasaaki p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT izutsukoji p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage AT ishizawakenichi p1086efficacyandsafetyofzandelisibadministeredbyintermittentdosinginjapanesepatientswithrelapsedrefractoryindolentbcellnonhodgkinslymphomaprimaryanalysisofthephase2studymirage |